General
Preferred name
daridorexant
Synonyms
DARIDOREXANT HYDROCHLORIDE ()
Nemorexant ()
ACT-541468 ()
Quviviq ()
ACT-541468A ()
Nemorexant hydrochloride ()
P&D ID
PD102489
CAS
1505484-82-1
Tags
available
drug
Approved by
EMA
FDA
First approval
2022
Drug Status
approved
Max Phase
Phase 4
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Daridorexant (ACT-541468) is a dual orexin receptor antagonist . It was designed and developed for potential to treat insomnia .
(GtoPdb)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
9
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2023/24
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
Guide to Pharmacology
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
23
Molecular Weight
450.16
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
1
Rotatable Bonds
4
Ring Count
5
Aromatic Ring Count
4
cLogP
4.27
TPSA
88.93
Fraction CSP3
0.3
Chiral centers
1.0
Largest ring
6.0
QED
0.5
QED
0.5
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
MOA
orexin receptor antagonist
Source data
